NO20024746L - Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom - Google Patents

Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom

Info

Publication number
NO20024746L
NO20024746L NO20024746A NO20024746A NO20024746L NO 20024746 L NO20024746 L NO 20024746L NO 20024746 A NO20024746 A NO 20024746A NO 20024746 A NO20024746 A NO 20024746A NO 20024746 L NO20024746 L NO 20024746L
Authority
NO
Norway
Prior art keywords
galantamine
alzheimer
disease
treatment
behavior associated
Prior art date
Application number
NO20024746A
Other languages
English (en)
Other versions
NO20024746D0 (no
Inventor
Wim Louis Julien Parys
Michael Pontecorvo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20024746D0 publication Critical patent/NO20024746D0/no
Publication of NO20024746L publication Critical patent/NO20024746L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20024746A 2000-04-03 2002-10-02 Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom NO20024746L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
PCT/EP2001/003553 WO2001074339A2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Publications (2)

Publication Number Publication Date
NO20024746D0 NO20024746D0 (no) 2002-10-02
NO20024746L true NO20024746L (no) 2002-11-28

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024746A NO20024746L (no) 2000-04-03 2002-10-02 Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom

Country Status (20)

Country Link
EP (1) EP1272192A2 (no)
JP (1) JP2003528913A (no)
KR (1) KR20020086911A (no)
CN (1) CN1430514A (no)
AU (2) AU2001265844B2 (no)
BG (1) BG107093A (no)
BR (1) BR0109770A (no)
CA (1) CA2310926C (no)
CZ (1) CZ20023543A3 (no)
EE (1) EE200200554A (no)
HR (1) HRP20020778A2 (no)
HU (1) HUP0300566A3 (no)
IL (1) IL152061A0 (no)
MX (1) MXPA02009777A (no)
NO (1) NO20024746L (no)
PL (1) PL361272A1 (no)
RU (1) RU2002129298A (no)
SK (1) SK15422002A3 (no)
WO (1) WO2001074339A2 (no)
ZA (1) ZA200207935B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
EP1651234B1 (en) 2003-07-25 2007-09-26 F. Hoffmann-La Roche Ag Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
ES2634421T3 (es) 2008-03-27 2017-09-27 Chase Pharmaceuticals Corporation Uso y composición para tratar la demencia
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
CA2986431C (en) * 2015-05-18 2020-04-14 Synaptec Development Llc Galantamine clearance of amyloid.beta.
CN117957003A (zh) * 2021-09-09 2024-04-30 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
WO2000030446A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
CA2358062C (en) * 1998-12-24 2006-12-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects

Also Published As

Publication number Publication date
IL152061A0 (en) 2003-05-29
HUP0300566A2 (hu) 2003-06-28
AU2001265844B2 (en) 2005-04-14
CN1430514A (zh) 2003-07-16
CA2310926A1 (en) 2000-10-04
WO2001074339A2 (en) 2001-10-11
EP1272192A2 (en) 2003-01-08
WO2001074339A3 (en) 2002-09-12
KR20020086911A (ko) 2002-11-20
AU6584401A (en) 2001-10-15
HUP0300566A3 (en) 2004-10-28
RU2002129298A (ru) 2004-03-27
CA2310926C (en) 2002-10-15
JP2003528913A (ja) 2003-09-30
PL361272A1 (en) 2004-10-04
CZ20023543A3 (cs) 2003-03-12
SK15422002A3 (sk) 2003-04-01
ZA200207935B (en) 2004-01-30
BG107093A (bg) 2003-06-30
BR0109770A (pt) 2003-02-04
NO20024746D0 (no) 2002-10-02
MXPA02009777A (es) 2003-03-27
HRP20020778A2 (en) 2004-04-30
EE200200554A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
NO20026199L (no) Forbindelser for behandling av Alzheimers sykdom
CY2020003I1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
PT2264018E (pt) Derivados de tioflavina para uso no diagnóstico da doença de alzheimer
SI1303272T1 (sl) Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
IS8135A (is) Þríhringtengdar indólafleiður og notkun þeirra til að meðhöndla Alzheimers-sjúkdóm
NO20025004L (no) Fremgangsmåte for fremstilling av 2,5-diketopiperaziner, 2,5- diketopiperaziner, dipeptider samt anvendelse derav
NO20032007L (no) Radiofarmasöytika for diagnostisering av Alzheimers sykdom
AR027945A1 (es) Uso de pramipexol en el tratamiento de transtornos de adiccion
NO20002686D0 (no) Forbedring av Peyronies sykdom
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
DK1296705T3 (da) Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
NO20024746L (no) Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom
NO20040659L (no) Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom
EP1364648A4 (en) CRYPTOTANSHINONE FOR THE PREVENTION AND RELIEF OF ALZHEIMER DISEASE
MA25509A1 (fr) Composition destinee au traitement de l'hepatite c
NO20030762D0 (no) Forbedret spesifisitet i behandling av sykdommer
DK1152762T3 (da) Anvendelse af desoxypeganin til behandling af Alzheimers demens
GB0008162D0 (en) Diagnosis and treatment of alzheimer's disease
AUPR227000A0 (en) Agents for the treatment of alzheimer's disease and screening and methods for the same
AU2002318888A1 (en) Metal Chelators for use in the treatment of Alzheimer's Disease
AU2002348687A1 (en) Macrocycles useful in the treatment of alzheimer's disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application